Annual Cash & Cash Equivalents
$49.30 M
-$38.40 M-43.78%
December 31, 2023
Summary
- As of February 12, 2025, MLYS annual cash & cash equivalents is $49.30 million, with the most recent change of -$38.40 million (-43.78%) on December 31, 2023.
- During the last 3 years, MLYS annual cash & cash equivalents has risen by +$47.90 million (+3399.22%).
- MLYS annual cash & cash equivalents is now -43.78% below its all-time high of $87.70 million, reached on December 31, 2022.
Performance
MLYS Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$97.27 M
+$29.42 M+43.35%
September 30, 2024
Summary
- As of February 12, 2025, MLYS quarterly cash and cash equivalents is $97.27 million, with the most recent change of +$29.42 million (+43.35%) on September 30, 2024.
- Over the past year, MLYS quarterly cash and cash equivalents has increased by +$47.97 million (+97.29%).
- MLYS quarterly cash and cash equivalents is now -29.64% below its all-time high of $138.25 million, reached on March 31, 2023.
Performance
MLYS Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
MLYS Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -43.8% | +97.3% |
| 3 y3 years | +3399.2% | -3.8% |
| 5 y5 years | +3399.2% | -3.8% |
MLYS Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -43.8% | +364.6% | -29.6% | +816.6% |
| 5 y | 5-year | -43.8% | +3399.2% | -29.6% | +816.6% |
| alltime | all time | -43.8% | +3399.2% | -29.6% | +816.6% |
Mineralys Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $97.27 M(+43.4%) |
| Jun 2024 | - | $67.86 M(-25.0%) |
| Mar 2024 | - | $90.42 M(+83.4%) |
| Dec 2023 | $49.30 M | $49.30 M(-42.9%) |
| Sep 2023 | - | $86.30 M(-14.7%) |
| Jun 2023 | - | $101.14 M(-26.8%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2023 | - | $138.25 M(+57.6%) |
| Dec 2022 | $87.70 M(+726.4%) | $87.70 M(+79.1%) |
| Sep 2022 | - | $48.95 M(+361.3%) |
| Dec 2021 | $10.61 M(+653.2%) | - |
| Dec 2021 | - | $10.61 M |
| Dec 2020 | $1.41 M | - |
FAQ
- What is Mineralys Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Mineralys Therapeutics?
- What is Mineralys Therapeutics annual cash & cash equivalents year-on-year change?
- What is Mineralys Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Mineralys Therapeutics?
- What is Mineralys Therapeutics quarterly cash and cash equivalents year-on-year change?
What is Mineralys Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of MLYS is $49.30 M
What is the all time high annual cash & cash equivalents for Mineralys Therapeutics?
Mineralys Therapeutics all-time high annual cash & cash equivalents is $87.70 M
What is Mineralys Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, MLYS annual cash & cash equivalents has changed by -$38.40 M (-43.78%)
What is Mineralys Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of MLYS is $97.27 M
What is the all time high quarterly cash and cash equivalents for Mineralys Therapeutics?
Mineralys Therapeutics all-time high quarterly cash and cash equivalents is $138.25 M
What is Mineralys Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, MLYS quarterly cash and cash equivalents has changed by +$47.97 M (+97.29%)